Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;12(1):315-324.
doi: 10.1002/cam4.4859. Epub 2022 Jun 19.

Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study

Mehrnoosh Shahrivar  1 , Caroline E Weibull  2 , Karin Ekström Smedby  2 , Bengt Glimelius  3 , Ingvar Syk  4 , Peter Matthiessen  5 , Caroline Nordenvall  1   6 , Anna Martling  1   6
Affiliations

Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study

Mehrnoosh Shahrivar et al. Cancer Med. 2023 Jan.

Abstract

Background: Results from previous studies indicate that use of aspirin may improve colorectal cancer (CRC) survival. The aim of this study was to assess whether use of aspirin influences overall survival or CRC-specific survival in an unselected cohort of patients diagnosed with CRC.

Methods: The study was performed using the Colorectal Cancer Data Base Sweden (CRCBaSe), a mega-linkage originating from the Swedish Colorectal Cancer Register, with additional linkages to other national health care registers. All patients diagnosed with primary CRC stage I-III treated with curative surgery, aged 18-85 years at diagnosis, from 2007 through 2016 were identified. Information on low-dose aspirin use was extracted from the Swedish Prescribed Drug Register. Exposure was defined as dispensed prescription for at least 6 months. Aspirin exposure was analyzed at the time of surgery (yes/no) and as a time-varying exposure during follow-up. Follow-up was restricted to a maximum 6 years, to model 5-year survival. Cox regression models were fitted to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Adjustments were performed for sex, age, year of diagnosis, Charlson comorbidity index, hypertension, and ASA score as potential confounders.

Results: A total of 32,195 patients diagnosed with CRC were included. 6764 (21%) were exposed to aspirin at the time of CRC surgery. The median time of follow-up was 4.2 years. Aspirin use at the time of surgery was not associated with all-cause (adjusted HR = 1.03, 95% CI: 0.97-1.08) nor CRC-specific mortality (adjusted HR = 0.99, 95% CI: 0.91-1.07). Aspirin use during follow-up was associated with increased all-cause (adjusted HR = 1.09, 95% CI: 1.04-1.15) but not CRC-specific mortality (adjusted HR = 0.98, 95% CI: 0.91-1.06). A CRC-specific effect associated with aspirin was noted from approximately 3 years following surgery.

Conclusions: In this large nation-wide cohort study there was no convincing association between aspirin use after CRC and OS or CRC-specific survival.

Keywords: aspirin; colorectal cancer; pharmacoepidemiology; survival.

PubMed Disclaimer

Conflict of interest statement

CEW is part of a research collaboration between Karolinska Institutet and Janssen Pharmaceutica NV for which Karolinska Institutet has received/receives grant support. The remaining authors have no disclosures or potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Overall survival (OS, top panel) and CRC‐specific survival (bottom panel) estimated with the Kaplan–Meier method (left panels) and standardized over age, sex, year of diagnosis, Charlson comorbidity index, and hypertension (right panels), by aspirin exposure at the time of CRC‐surgery
FIGURE 2
FIGURE 2
Time‐varying hazard ratios (HRs) with 95% confidence intervals (CIs) as measure of the association between aspirin use time of CRC surgery (non‐users as reference) and all‐cause (left panel) and colorectal cancer (CRC)‐specific mortality (right panel) in patients with colorectal cancer adjusted for age, sex, year of diagnosis, Charlson comorbidity index, hypertension, and ASA score
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. - PubMed
    1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683‐691. - PubMed
    1. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241‐246. - PubMed
    1. Flossmann E, Rothwell PM. Effect of aspirin on long‐term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603‐1613. - PubMed
    1. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long‐term daily use of adult‐strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608‐615. - PubMed

Publication types